(Total Views: 276)
Posted On: 07/21/2017 4:26:01 AM
Post# of 721
NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Commences Lab Work with National Research Council of Canada
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced the start of laboratory work under its collaborative research project with the National Research Council of Canada (“NRC”). “We are delighted to have commenced formulation development and characterization work together with the NRC,” John Docherty, president of Lexaria Bioscience, stated in the news release. “The NRC team has extensive knowledge and experience in the field of lipid based delivery systems relating to pharmaceutical products, natural health products and functional foods. This collaboration will significantly assist Lexaria in further developing and characterizing its IP portfolio.” Moving forward, several studies will be initiated in an effort to optimize Lexaria’s patented technology enabling delivery of lipophilic active agents within foods, beverages, capsules and other ingestible formats. Per this morning’s update, practical applications of this work could include further broadening or strengthening of Lexaria’s intellectual property portfolio and may also provide the foundation for new commercial arrangements.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced the start of laboratory work under its collaborative research project with the National Research Council of Canada (“NRC”). “We are delighted to have commenced formulation development and characterization work together with the NRC,” John Docherty, president of Lexaria Bioscience, stated in the news release. “The NRC team has extensive knowledge and experience in the field of lipid based delivery systems relating to pharmaceutical products, natural health products and functional foods. This collaboration will significantly assist Lexaria in further developing and characterizing its IP portfolio.” Moving forward, several studies will be initiated in an effort to optimize Lexaria’s patented technology enabling delivery of lipophilic active agents within foods, beverages, capsules and other ingestible formats. Per this morning’s update, practical applications of this work could include further broadening or strengthening of Lexaria’s intellectual property portfolio and may also provide the foundation for new commercial arrangements.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
